CKD-387
/ Chong Kun Dang
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
May 03, 2024
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fasting Conditions
(clinicaltrials.gov)
- P1 | N=37 | Completed | Sponsor: Chong Kun Dang Pharmaceutical
New P1 trial • Metabolic Disorders
May 03, 2024
Clinical Study to Evaluate Pharmacokinetic Profiles and Safety of CKD-387 Under Fasting Condition
(clinicaltrials.gov)
- P1 | N=40 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Recruiting ➔ Completed
Trial completion • Metabolic Disorders
May 03, 2024
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fed Conditions
(clinicaltrials.gov)
- P1 | N=31 | Completed | Sponsor: Chong Kun Dang Pharmaceutical
New P1 trial • Metabolic Disorders
January 06, 2023
Clinical Study to Evaluate Pharmacokinetic Profiles and Safety of CKD-387 Under Fasting Condition
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Chong Kun Dang Pharmaceutical
New P1 trial • Metabolic Disorders
1 to 4
Of
4
Go to page
1